Samadhan G. Kshirsagar

Ahmedabad, GJ, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease.

Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease.

Journal: Experimental neurology

Published: December 13, 2024

HIF-Prolyl Hydroxylase Inhibitor Desidustat Increases Pyruvate Kinase Activity and Reduces Oxidative Stress in Red Blood Cells, Causes Erythrocytosis in Thalassaemic Mice, and Reduces Sickling in Sickle Cell Patient's Blood.

HIF-Prolyl Hydroxylase Inhibitor Desidustat Increases Pyruvate Kinase Activity and Reduces Oxidative Stress in Red Blood Cells, Causes Erythrocytosis in Thalassaemic Mice, and Reduces Sickling in Sickle Cell Patient's Blood.

Journal: Drug development research

Published: November 18, 2024

Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models.

Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models.

Journal: Journal of diabetes and its complications

Published: October 24, 2024

Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammation.

Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammation.

Journal: Inflammopharmacology

Published: September 30, 2024

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases.

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases.

Journal: Drug research

Published: July 11, 2024

Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice.

Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice.

Journal: International immunopharmacology

Published: July 09, 2024

Comparative Analysis of the Effect of Sex and Age on the Hematological and Biochemical Profile of BALB/c and C57BL/6 Inbred Mice.

Comparative Analysis of the Effect of Sex and Age on the Hematological and Biochemical Profile of BALB/c and C57BL/6 Inbred Mice.

Journal: Journal of the American Association for Laboratory Animal Science : JAALAS

Published: July 08, 2024

HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.

HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.

Journal: Toxicology and applied pharmacology

Published: October 16, 2023

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.

Journal: Current research in pharmacology and drug discovery

Published: November 16, 2021

Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation.

Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation.

Journal: Toxicology and applied pharmacology

Published: October 14, 2021

Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19).

Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19).

Journal: Bioorganic & medicinal chemistry letters

Published: August 12, 2021

Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice.

Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice.

Journal: Drug research

Published: July 26, 2021

Showing 1-12 of 41

Last Updated: 09/26/2026